Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05321147 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma That Express KIR3DL2
A Phase 1 study, sponsored by Innate Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT05321147 is a Phase 1 study that has completed, run by Innate Pharma. The registered enrollment target is 20 participants.
The verdict
NCT05321147, a Phase 1 study, has completed, sponsored by Innate Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is a multi-center phase Ib study, which evaluates the safety and efficacy of lacutamab monotherapy in patients with relapsed/refractory peripheral T-cell lymphoma that express KIR3DL2.
Interventions
- BIOLOGICAL lacutamab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2022-03-17 |
| Est. Completion | 2024-02-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05321147
The ClinicalTrials.gov registry entry for NCT05321147 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Innate Pharma, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which lacutamab is the first listed.
NCT05321147 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05321147 about?
NCT05321147 is a clinical study titled "Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma That Express KIR3DL2". This is a multi-center phase Ib study, which evaluates the safety and efficacy of lacutamab monotherapy in patients with relapsed/refractory peripheral T-cell lymphoma that express KIR3DL2.
What is the current status of trial NCT05321147?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2022-03-17. Estimated completion is 2024-02-08.
What interventions are being tested in trial NCT05321147?
The interventions under investigation include: lacutamab (BIOLOGICAL).
Who is sponsoring clinical trial NCT05321147?
This trial is sponsored by Innate Pharma, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.